UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549 

FORM 8-K 

CURRENT REPORT 

Pursuant to Section 13 or 15(d) of 

the Securities Exchange Act of 1934 

Date of Report: January 2, 2018 

REGENERON PHARMACEUTICALS, INC. 

(Exact name of registrant as specified in its charter) 

New York 

(State or other jurisdiction of incorporation) 

 [DATA_TABLE_REMOVED]  

Registrant’s telephone number, including area code: (914) 847-7000 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). 

Emerging growth company o 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 

Effective January 5, 2018, Robert J. Terifay has resigned as Executive Vice President, Commercial of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) and related positions. Mr. Terifay has been placed on a personal leave of absence as he requested for medical reasons through July 31, 2018. During his leave of absence, he will be able to participate in the Company’s health insurance plans and other similar plans, but will not receive any cash compensation. After the conclusion of his leave of absence on July 31, 2018, Mr. Terifay will retire. Thereafter, Mr. Terifay will be eligible for his continued participation in Regeneron’s health insurance plans subsidized by Regeneron through January 31, 2020. The Company is conducting a search for Mr. Terifay’s replacement. 

SIGNATURES 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. 

  [DATA_TABLE_REMOVED]